Pharmica, Merck, Genzyme Strategies
Finding The Right Metrics
What to count (or not), and why.
A commercial North Carolina institutional review board (IRB), Copernicus Group IRB, has received ISO 9001 certification. The company has a paperless system to manage clinical trial forms. “To our knowledge, CGIRB is the only central IRB that has achieved this certification. It is further evidence to our clients and the subjects of research studies that the quality of our services and our strong business practices are unsurpassed,” said Bruce Tomason, CEO. Here's a release. There's a split between early- and late-phase contract research organizations (CROs), according to this wire service article. Some small sponsors and biotechnology firms are delaying the launch of projects, analysts say, favoring late-phase specialists. Health Decisions, a technology-oriented contract research organization, appointed a new chief technology officer, Bryan Minihan. He'll be working on the company's system that, among other features, supports adaptive clinical trials. Minihan previously worked at GSK, Accenture, Intuit, and Cisco. “I’m excited to be…more...
Large life science companies have fired untold tens of thousands of employees during every year of the ongoing downturn—a period of both financial chaos and pharmaceutical mega-mergers. Here's one estimate, and…more...
Some people are happy with incremental progress. A long career in drug safety has left Michael Ibara searching for a bigger leap forward. He's the architect of a potential alternative to…more...
Most of the ClinPage podcasts are done in a pretty typical Q&A format. Today, however, we're posting a different type of audio: some snippets from the 2009 Clinical Trials Congress, held…more...
The best minds on Wall Street like Pfizer’s $68 billion acquisition of Wyeth. Last week, to take just one example, a prominent firm (which advised Pfizer on the merger) said it believes its client is poised for a revival once it has Wyeth drugs in its pipeline.Yesterday, Merck took a page from the same play book, buying…more...
One surprising aspect of the clinical trial landscape is just how few PhDs and physicians share their knowledge, either as industry insiders or academic researchers. The vastness of the global research enterprise does necessarily involve large numbers of other professionals. We know that. But hearing from the experts now and then is nice. We get a large…more...
Say you need someone to do something for you in Singapore. It turns out it’s rude to leave someone a few voice mail messages. Even several email requests are a bit of a no-no. Instead, communication via so-called “text” or short messaging systems (SMS) is the norm and the Emily-Post approved technique. That works for Pfizer. The…more...
Yesterday, Pfizer announced that it was abandoning new projects in cardiovascular disease. This was about as expected as Federal Express investing in horse-based shipping routes. Then GSK leaked word it was cutting 850 jobs, or 6 percent of its R&D headcount, in the wake of an arrival of a new CEO, Andrew Witty, and the quiet departures…more...
What to count (or not), and why.
A report from the Clinical Trials Congress about risk. One message: start a regulatory conversation early. And consult your preclinical team.
With impressive numbers, Pfizer’s Mike Collins talked about how the company is streamlining its clinical trial process.
Sponsors are abuzz about site relationship management (SRM). In the first installment of our series, Wyeth describes its efforts to become the sponsor of choice.
A clarification to recent ClinPage coverage of Pfizer at DIA.
A clarification of our report from DIA.
News for June 1.
Organizations
Conferences
Info & Opinion
© 2010 ClinPage. All Rights Reserved.